Seres Therapeutics, Inc. (MCRB)
2.09
-0.04
(-1.88%)
USD |
NASDAQ |
Oct 23, 16:00
2.10
+0.01
(+0.48%)
After-Hours: 20:00
Seres Therapeutics Enterprise Value : 61.59M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 61.59M |
| October 22, 2026 | 61.98M |
| October 21, 2026 | 63.65M |
| October 20, 2026 | 63.75M |
| October 19, 2026 | 64.83M |
| October 16, 2026 | 65.23M |
| October 15, 2026 | 65.91M |
| October 14, 2026 | 64.83M |
| October 13, 2026 | 65.91M |
| October 12, 2026 | 67.39M |
| October 09, 2026 | 67.68M |
| October 08, 2026 | 66.90M |
| October 07, 2026 | 67.78M |
| October 06, 2026 | 69.55M |
| October 05, 2026 | 69.06M |
| October 02, 2026 | 69.94M |
| October 01, 2026 | 69.84M |
| September 30, 2026 | 73.97M |
| September 29, 2026 | 75.25M |
| September 28, 2026 | 75.64M |
| September 25, 2026 | 75.64M |
| September 24, 2026 | 76.63M |
| September 23, 2026 | 78.30M |
| September 22, 2026 | 80.56M |
| September 21, 2026 | 81.05M |
| Date | Value |
|---|---|
| September 18, 2026 | 80.36M |
| September 17, 2026 | 81.34M |
| September 16, 2026 | 82.42M |
| September 15, 2026 | 86.26M |
| September 14, 2026 | 87.53M |
| September 11, 2026 | 90.29M |
| September 10, 2026 | 91.17M |
| September 09, 2026 | 92.94M |
| September 08, 2026 | 95.69M |
| September 04, 2026 | 97.26M |
| September 03, 2026 | 96.48M |
| September 02, 2026 | 95.49M |
| September 01, 2026 | 91.96M |
| August 31, 2026 | 89.30M |
| August 28, 2026 | 91.27M |
| August 27, 2026 | 89.70M |
| August 26, 2026 | 87.83M |
| August 25, 2026 | 90.19M |
| August 24, 2026 | 86.85M |
| August 21, 2026 | 85.86M |
| August 20, 2026 | 85.96M |
| August 19, 2026 | 87.04M |
| August 18, 2026 | 83.70M |
| August 17, 2026 | 85.37M |
| August 14, 2026 | 85.67M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.581M |
| Revenue (Quarterly) | 0.736M |
| Total Expenses (Quarterly) | -3.845M |
| EPS Diluted (Quarterly) | 0.47 |
| Gross Profit Margin (Quarterly) | 8.97% |
| Earnings Yield | -109.0% |
| Normalized Earnings Yield | -85.15 |